131 related articles for article (PubMed ID: 38050720)
1. Effect of CYP3A4*22, CYP3A5*3 and POR*28 genetic polymorphisms on calcineurin inhibitors dose requirements in early phase renal transplant patients.
Ebid AI; Ismail DA; Lotfy NM; Mahmoud MA; El-Sharkawy M
Pharmacogenet Genomics; 2024 Feb; 34(2):43-52. PubMed ID: 38050720
[TBL] [Abstract][Full Text] [Related]
2. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
Li DY; Teng RC; Zhu HJ; Fang Y
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
[TBL] [Abstract][Full Text] [Related]
3. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients.
Kuypers DR; de Loor H; Naesens M; Coopmans T; de Jonge H
Pharmacogenet Genomics; 2014 Dec; 24(12):597-606. PubMed ID: 25322286
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
8. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
[TBL] [Abstract][Full Text] [Related]
9. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
10. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
11. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
12. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
13. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
[TBL] [Abstract][Full Text] [Related]
14. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
15. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
Cvetković M; Zivković M; Bundalo M; Gojković I; Spasojević-Dimitrijeva B; Stanković A; Kostić M
Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
17. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.
Phupradit A; Vadcharavivad S; Ingsathit A; Kantachuvesiri S; Areepium N; Sra-Ium S; Auamnoy T; Sukasem C; Sumethkul V; Kitiyakara C
Ther Drug Monit; 2018 Oct; 40(5):549-557. PubMed ID: 29878980
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
20. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
